Home/Pipeline/ARCT-2301

ARCT-2301

Cystic Fibrosis (CFTR correction)

Phase 1bActiveNCT05679687

Key Facts

Indication
Cystic Fibrosis (CFTR correction)
Phase
Phase 1b
Status
Active
Company

About Arcturus Therapeutics

Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.

View full company profile